STOCK TITAN
  1. Home
  2. News
  3. BCRX

BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
BioCryst Pharmaceuticals to present at Wells Fargo Healthcare Conference and H.C. Wainwright Global Investment Conference
Positive
  • None.
Negative
  • None.

RESEARCH TRIANGLE PARK, N.C., Aug. 23, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 2023 Wells Fargo Healthcare Conference on Wednesday, September 6th in Boston at 3:00 p.m. ET and the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13th in New York at 12:30 p.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and many global markets. BioCryst has active programs to develop oral medicines for multiple targets across the complement system, including BCX10013, an oral Factor D inhibitor in clinical development. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com


Stock BCRX logo
BioCryst Pharmaceuticals Inc

NASDAQ:BCRX

BCRX Rankings

#2497 Ranked by Market Cap
#4914 Ranked by Stock Gains
N/A Ranked by Dividends

BCRX Latest News

May 3, 2024
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 22, 2024
BioCryst to Report First Quarter 2024 Financial Results on May 6
Apr 17, 2024
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
Apr 3, 2024
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 25, 2024
BioCryst to Present at Upcoming Investor Conferences

BCRX Stock Data

918.17M
190.88M
1.21%
88.11%
15.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
DURHAM

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.